Instead of waiting for allergy patients to have symptoms on study days, Dr. Abelson’s team created a model to induce the allergic reaction in a controlled way. This 'Conjunctival Allergy Challenge' allowed for precise, predictable testing of new drugs, dramatically speeding up development.

Instead of following a traditional, slower Phase 1/2/3 trial structure, eGenesis leveraged the FDA's Expanded Access (compassionate use) pathway for its initial human cases. This strategy allowed for rapid learning from real-world patients, putting them two years ahead of schedule.

Many firms view patient engagement as a compliance task that adds cost. However, data shows integrating patient experience into development from the start speeds up clinical trial recruitment and execution, reduces FDA amendments, and accelerates time-to-market, providing clear ROI.

Syndax bypasses the lengthy initial lab phase by in-licensing promising science from external sources. This allows their internal experts to focus directly on clinical development in areas of high unmet medical need, a key strategy behind getting two drug approvals in two years.

The FDA now allows a single, well-designed pivotal trial instead of the traditional two. This reform significantly cuts costs by $100M-$300M and shortens development timelines, enabling companies to test twice as many potential drugs with the same capital.

The lack of new drugs for pre-term babies is a market failure. For three decades, progress has been crippled by a dual challenge: venture capital funds avoiding pediatric studies and regulatory agencies lacking recent experience in evaluating neonatal treatments, creating a vicious cycle of stagnation.

Instead of a total overhaul, we can accelerate trials with three changes: 1) A simple patient opt-in registry for trial participation. 2) Collaborative platform trials testing multiple drugs against one control group. 3) A shared database for all trial data, including failures.

Acadia's R&D process starts by considering what will ultimately matter to patients, physicians, and payers. This "end in mind" approach ensures clinical trials are designed to demonstrate meaningful, commercially relevant benefits. It forces realism about a drug's potential impact early in development, avoiding wasted resources on therapies that won't be adopted.

A massive disparity exists between pediatric (85 drugs in 75 years) and adult (118 drugs in 8 years) cancer drug approvals. This stems from a flawed industry model that treats biologically different children as small adults, hindering effective R&D.